ML-9
货号：
10010236-250mg 基本售价：
7084.0 元 规格：
250 mg
产品信息
概述| 货号 | 10010236-250mg |
| 描述 | ML-9 was originally identified as a selective Ca2+-calmodulin-dependent myosin light chain kinase inhibitor. Concentrations from 10-100 µM are effective at inhibiting vascular smooth muscle tension and reducing intracellular Ca2+concentrations.1 ML-9 also inhibits PKB/Akt activity with an IC50 range of 10-50 µM in rat primary adipocytes. This results in a specific inhibition of insulin-stimulated glucose transport and GLUT4/IGF II receptor translocation to the plasma membrane yet does not interfere with the antilipolytic effect of insulin.2 Additionally, ML-9 inhibits other serine/threonine kinases including PKA (IC50 = ~20 µM), p90 S6 (IC50 = ~50 µM), and MAP kinase (IC50 = ~35 µM).2 |
性能| 供应商 | Cayman |
| 应用文献 |
1.Ito, S.,Kume, H.,Honjo, H., et al. ML-9, a myosin light chain kinase inhibitor, reduces intracellular Ca2+ concentration in guinea pig trachealis. European Journal of Pharmacology 486, 325-333 (2004).
2.Smith, U.,Carvalho, E.,Mosialou, E., et al. PKB inhibition prevents the stimulatory effect of insulin on glucose transport and protein translocation but not the antilipolytic effect in rat adipocytes. Biochemical and Biophysical Research Communications 268, 315-320 (2000).
|
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 361.3 |
| 分子式 | C15H17ClN2O2S • HCl |
| CAS号 | 105637-50-1 |
| 稳定性 | ≥ 2 years |
声明| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |
